Sanofi-aventis receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Sanofi ADR (SNY)
The Sanofi ADR share price today is 43.56, view NASDAQ SNY stock exchange data. Track the latest Sanofi ADR share price with real-time updates on SNY stock performance including market cap, day range, 52-week range and dividend yield. Access SNY charts, earnings dates and analyst estimates to support your investment decisions.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
43.43
43.90
52 wk Range
40.89
52.68
High dividend Yield
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
43.4343.90
52 wk Range
40.8952.68
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(4.06%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(4.06%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
SNY Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Price Target
53.72
Upside
+23.33%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
High shareholder yield
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy
Analyst Ratings
5 Buy
5 Hold
0 Sell
Ratings:
10 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 53.72
(+23.33% Upside)
Sanofi ADR Earnings Call Summary for Q2/2026
- Sanofi Q2 2026 EPS of $2.39 beat estimates of $1.09; revenue rose 17.8% to $13.25B, driven by Dupixent sales exceeding EUR 5B for first time.
- Stock fell 5.33% premarket to $42.46 despite beat, as investors focused on management's warning of slower second-half growth and pipeline concerns.
- Full-year 2026 guidance raised to ~10% sales growth at constant FX, but vaccine sales expected to decline; 2030 Dupixent target raised to EUR 25B.
- CEO Garijo emphasized need for 'greater scientific rigor' in R&D after pipeline setbacks; company now open to larger M&A deals aligned with strategy.
- Key risks include heavy reliance on Dupixent, ongoing Regeneron alliance tensions, vaccine business pressure, and expected growth deceleration in H2 2026.
Last Updated: 30-07-2026, 06:20 pm
Read Full TranscriptEarnings
Latest Release
30-07-2026
EPS / Forecast
2.39 / 1.09
Revenue / Forecast
13.25B / 13.02B
Compare SNY to Peers and Sector
Metrics to compare | SNY | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSNYPeersSector | |
|---|---|---|---|---|
P/E Ratio | 23.0x | 19.7x | −0.4x | |
PEG Ratio | −0.41 | 0.17 | 0.00 | |
Price/Book | 1.3x | 1.7x | 2.6x | |
Price / LTM Sales | 1.9x | 2.5x | 3.1x | |
Upside (Analyst Target) | 25.1% | 8.7% | 47.5% | |
Fair Value Upside | Unlock | 14.1% | 5.9% | Unlock |
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine’s AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV’574, for treatment of ulcerative colitis and Crohn’s disease; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Sanofi ADR (SNY) Share Price Today?
The Sanofi ADR share price today is 43.56.
What is the current Sanofi ADR (SNY) share price and day range?
As of 12-08-2026, the Sanofi ADR share price is 43.56, with a previous close of 43.56. The share price has ranged from 43.43 to 43.90 today, while the 52-week range spans from 40.89 to 52.68.
What Is the Sanofi ADR Market Cap?
As of today, Sanofi ADR market cap is 104.21B.
Does Sanofi ADR Pay Dividends? What's The Current Dividend Yield?
The Sanofi ADR dividend yield is 4.06%.
What Is the Sanofi ADR (SNY) Share Price Target?
The average 12-month share price target for Sanofi ADR is 53.72, with a high estimate of 63 and a low estimate of 45. 5 analysts recommend buying, while 0 suggest selling, with an overall rating of Buy and +23.33% Upside potential.
What Is Sanofi ADR's Earnings Per Share (TTM)?
The Sanofi ADR EPS (TTM) is 3.25.
When Is the Next Sanofi ADR Earnings Date?
Sanofi ADR will release its next earnings report on 30-10-2026.
From a Technical Analysis Perspective, Is SNY a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
What Stock Exchange Does Sanofi ADR Trade On?
Sanofi ADR is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Sanofi ADR?
The stock symbol for Sanofi ADR is "SNY."
How Many Times Has Sanofi ADR Stock Split?
Sanofi ADR has split 0 times.
How Many Employees Does Sanofi ADR Have?
Sanofi ADR has 74846 employees.
What Is the SNY Premarket Price?
SNY's last pre-market stock price is 43.50. The pre-market share volume is 15,010.00, and the stock has changed by -0.06, or -0.14%.
What Is the SNY After Hours Price?
SNY's last after hours stock price is 43.99, the stock has changed by 0.43, or 0.99%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.